Compare BioNTech SE - ADR (BNTX) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Alphabet Inc Class A — how do they compare? BioNTech SE - ADR trades at $90.35 (market cap $22.86B), while Alphabet Inc Class A trades at $372.13 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 191.2× BioNTech SE - ADR's market cap, and Alphabet Inc Class A pays a 0.24% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | GOOGL | |
|---|---|---|
Market Cap | $22.86B | $4.37T |
Sector | Health | Media |
52-Week High | $119.34 | $402.62 |
52-Week Low | $83.89 | $182.00 |
Enterprise Value | $6.53B | $4.34T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Alphabet (GOOGL) stock trades at $371.52, up 5.39% in 24 hours, supported by strong earnings beats and robust financials. The technical picture is neutral with bullish moving averages, while fundamentals show impressive revenue growth to $402.84B in 2025 and a net income margin of 37.92%. Recent news highlights AI-driven growth opportunities and YouTube's subscription price increase. Analyst consensus remains overwhelmingly bullish with an average price target of $431.78.
Outlook is positive given consistent earnings outperformance, expanding AI integration across services, and strong cash flow generation. Key risks include antitrust scrutiny, competitive pressure in AI and cloud, and market volatility. The stock offers growth exposure to AI leadership but faces regulatory and execution challenges in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
